Bristol Myers Squibb and Hengrui Pharma signed a collaboration covering 13 early-stage programs in oncology, hematology, and immunology that could reach more than $15 billion in total value. Under the agreement, Hengrui will oversee early clinical development to accelerate proof-of-concept, while BMS retains exclusive worldwide rights outside Hengrui’s territory and receives tiered royalties on sales commercialized outside China, Hong Kong, and Macau. Financially, BMS agreed to pay up to $950 million over two years, including a $600 million upfront payment and two $175 million anniversary payments, subject to milestones. The structure—upfront-heavy and discovery-and-early-development focused—signals continued willingness by large-cap pharma to buy speed and platform capability from regional innovators while maintaining geographic partitioning control.